# Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors

> **NCT00305084** · PHASE1 · COMPLETED · sponsor: **AGC Biologics S.p.A.** · enrollment: 15 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** NGR-hTNF
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT00305084
- **Lead sponsor:** AGC Biologics S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02-28
- **Primary completion:** 2007-05-08
- **Final completion:** 2007-05-08
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00305084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00305084, "Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00305084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*